title: Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
abstract: BACKGROUND
  A considerable number of patients develop sinusoidal obstruction syndrome (SOS) after oxaliplatin-based chemotherapy for colorectal liver metastases (CLMs). SOS is associated with adverse outcomes after major hepatectomy. Hyaluronic acid (HA) is a marker of hepatic sinusoidal endothelial cell function and may serve as an accurate marker of SOS. This study aimed to assess the value of systemic HA levels and fractional extraction (FE) of HA by the splanchnic area and liver as markers of SOS after oxaliplatin-based chemotherapy for CLMs.
  
  
  METHODS
  Forty patients were studied. The presence of SOS was assessed histopathologically. Blood samples from the radial artery and portal and hepatic veins were collected. HA levels were determined by ELISA and the FE of HA was estimated.
  
  
  RESULTS
  SOS was present in 23 patients, 11 of whom demonstrated moderate or severe SOS. Preoperative HA levels were significantly higher in patients with moderate or severe SOS (group B, n = 11) compared to patients with no or mild SOS (group A, n = 29) (51.6 ± 10.2 ng/mL vs. 32.1 ± 3.5 ng/mL, p = 0.030). A cutoff HA level of 44.1 ng/mL yielded a sensitivity of 67 % and specificity of 83 % for detection of SOS. The positive predictive value was 50 % and the negative predictive value 91 %. Both groups exhibited a similar FE of HA by the splanchnic area (-7.9 ± 8.5 % in Group A vs. 7.3 ± 3.6 % in Group B, p = 0.422) and liver (-10.7 ± 6.2 % in Group A vs. 4.6 ± 2.3 % in Group B, p = 0.265).
  
  
  CONCLUSIONS
  Systemic HA levels can be used to detect patients at risk of SOS after oxaliplatin-based chemotherapy for CLMs. Additional investigations into the presence of SOS are indicated in patients with elevated HA levels.
authors: Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands. m.vandenbroek@maastrichtuniversity.nl
authors: Maartje A J
authors: MA
authors: van den Broek
authors: Celien P H
authors: CP
authors: Vreuls
authors: Ali
authors: A
authors: Winstanley
authors: Rob L H
authors: RL
authors: Jansen
authors: Annemarie A
authors: AA
authors: van Bijnen
authors: Simon A W G
authors: SA
authors: Dello
authors: Marc H
authors: MH
authors: Bemelmans
authors: Cornelis H C
authors: CH
authors: Dejong
authors: Ann
authors: A
authors: Driessen
authors: Steven W M
authors: SW
authors: Olde Damink
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000068258:Bevacizumab; D015415:Biomarkers / Q000097:blood; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000473:pathology*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006498:Hepatectomy; D006503:Hepatic Veins; D006504:Hepatic Veno-Occlusive Disease / Q000097:blood* / Q000139:chemically induced; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D011169:Portal Vein; D011237:Predictive Value of Tests; D011446:Prospective Studies; D017534:Radial Artery; D012720:Severity of Illness Index
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D006820:Hyaluronic Acid; D005472:Fluorouracil